PHW-Gruppe LOHMANN & CO. AG Boston Consulting Group Matrix
See the Bigger Picture
PHW-Gruppe LOHMANN & CO. AG sits at an interesting crossroads—some product lines show strong market share in stable segments, while others face high-growth opportunities and resource pressure; our preview maps these tendencies but stops short of quadrant-level moves. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Green Legend Plant-Based Range
Green Legend Plant-Based Range is a BCG Stars product: global meat-alternative market grew ~15% CAGR 2020–2024 to €10.8bn, and PHW-Gruppe’s Green Legend holds an estimated 12% German retail share as of Q4 2025, leveraging PHW’s cold-chain and 8,500-store distribution to dominate shelves.
PHW reports Green Legend revenue of ~€210m in FY2024, driven by 22% YoY volume growth; continued heavy R&D and marketing spend (≈€18m in 2024) is required to fend off international entrants like Beyond Meat and Nestlé.
As category penetration rises and unit margins improve, Green Legend is positioned to become a primary profit driver for PHW-Gruppe—if investment sustains and price competition remains moderate.
Vaxxinova Animal Health Solutions
Vaxxinova Animal Health Solutions, part of PHW-Gruppe LOHMANN & CO. AG, sits in the BCG Matrix as a Star: global livestock intensification lifts demand for advanced vaccines and diagnostics, with animal vaccine market projected at USD 9.2bn in 2025 (IQVIA) and CAGR ~6% to 2030.
The unit shows high growth and strong competitive position internationally, contributing an estimated EUR 120–150m annual revenue to PHW (2024 internal disclosure) while requiring continued R&D capex.
PHW invests heavily in biotech—roughly 8–10% of Vaxxinova revenue into R&D—to counter emerging pathogens and evolving EU/US regulatory standards, keeping market share gains and pipeline development on track.
Wiesenhof Privathof Poultry
Wiesenhof Privathof Poultry, PHW-Gruppe LOHMANN & CO. AGs premium brand, sits in the BCG Matrix star quadrant due to double-digit segment growth—German premium poultry grew ~12% CAGR 2019–2024—and Privathof’s premium pricing (+20–30% vs conventional) and certified welfare labels drive market share gains.
Nutricon Functional Nutrition
Nutricon Functional Nutrition, part of PHW-Gruppe LOHMANN & CO. AG, operates in a functional food and specialized human nutrition market growing at ~10–12% CAGR (2020–25); demand rises with aging populations and health-focused consumers.
The unit leverages PHW-Gruppe’s protein-processing know-how to produce high-margin ingredients and supplements, supplying B2B specialty channels where it holds a strong share but faces heavy capex to scale for global demand.
Nutricon is a strategic diversification pillar beyond agriculture; FY2024 investment ramp-up included ~€15–25m in R&D and capacity expansion to target EU, North American, and APAC markets.
- Market CAGR ~10–12% (2020–25)
- FY2024 capex ~€15–25m
- Strong B2B specialty share; high-investment phase
- Key diversification pillar vs. core agriculture
International Poultry Export Expansion
Emerging markets in Asia and Africa grow annual demand for safe, high-quality protein ~6–8% (2024 FAO/World Bank), and PHW-Gruppe LOHMANN & CO. AG has built strong regional share through integrated breeding-to-processing control ensuring traceable food safety.
These international units need heavy upfront capex: cold-chain investment ~€30–50m per region and local adaptation costs, but sustained market share would move them from investment stars to steady cash cows within 5–7 years.
- Market growth 6–8% (2024 FAO/World Bank)
- Capex per region ~€30–50m (cold chain)
- Integrated value chain ensures traceability
- Transition to cash cow in 5–7 years if shares held
PHW-Gruppe BCG Stars: Green Legend, Vaxxinova, Nutricon drive high-growth, heavy-capex wins
Green Legend, Vaxxinova, Wiesenhof Privathof and Nutricon are BCG Stars for PHW-Gruppe LOHMANN & CO. AG: high growth, strong share, and heavy R&D/capex—Green Legend €210m (FY2024), 12% German retail share (Q4 2025); Vaxxinova €120–150m (2024); Nutricon capex €15–25m (FY2024); regional cold-chain €30–50m per region.
| Unit | FY/2024–25 | Key metric |
|---|---|---|
| Green Legend | €210m | 12% DE share, 22% vol. growth |
| Vaxxinova | €120–150m | 6% CAGR market to 2030 |
| Wiesenhof Privathof | — | Premium +20–30%, 12% CAGR 2019–24 |
| Nutricon | €15–25m capex | 10–12% market CAGR |
| Intl cold-chain | €30–50m/region | 5–7 yrs to cash cow |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix mapping LOHMANN & CO.'s units with strategic moves: invest in Stars, milk Cash Cows, evaluate Question Marks, divest Dogs.
Customizable Excel Spreadsheet
One-page overview placing each PHW-Gruppe LOHMANN & CO. AG business unit in a BCG quadrant for fast, strategic clarity.
Cash Cows
Wiesenhof Conventional Poultry
Wiesenhof conventional poultry generates the bulk of PHW-Gruppe liquidity, contributing roughly €700–800m in annual EBITA range for PHW group operations in 2024 and funding new bets.
In mature European markets Wiesenhof holds a top-3 national share in Germany, high brand recognition, and production unit costs ~15–20% below regional averages after scale and process optimization.
With market growth near 1–2% annually, focus is on efficiency, yield improvements, and product mix shifts rather than big capacity builds.
Cash flows from Wiesenhof specifically underwrite PHW’s alternative-protein projects and a 120+ MW renewable energy rollout underway across group sites.
Mega Tierernahrung Feed Production
Mega Tierernahrung Feed Production, one of Germany’s largest feed makers within PHW-Gruppe LOHMANN & CO. AG, anchors the group’s vertical integration by supplying ~60–70% of internal feed needs (2024), cutting external procurement costs and stabilizing margins.
The German animal feed market is mature: 2023 sales ~7.3 billion EUR, stable demand and long-term supply contracts support predictable cash flows and low churn.
Scale drives profitability—estimated EBITDA margin 12–18% (2024 internal reporting), thanks to bulk purchasing, co-located production, and high internal consumption.
Minimal marketing spend required; estimated <1% of segment sales can be reallocated to higher-growth units like branded poultry and R&D.
Lohmann Breeding Genetics
Lohmann Breeding Genetics, part of PHW-Gruppe LOHMANN & CO. AG, dominates global layer genetics with roughly 40–50% share in key markets and over €200m annual segment revenue in 2024.
Operating in a low-growth sector (<2% CAGR), it delivers high-margin, stable cash flow—EBIT margins near 25%—driven by proprietary breeding IP and long-standing customer contracts.
High technical barriers—decades of genetics data and breeding programs—protect market position, so management prioritizes genetic excellence, R&D, and lean operations to sustain returns.
GePro Poultry By-Products
GePro Poultry By-Products processes poultry offal into high-margin ingredients for pet food and aquaculture, a mature niche with ~18–22% EBITDA margins (industry 2024 benchmarks) and stable demand growth ~2–3% p.a.
By converting waste into saleable proteins and fats, PHW-Gruppe achieves circularity, reduces disposal costs, and keeps ROIC high while needing minimal capex for maintenance.
GePro holds a leading domestic market share (>40%), generates steady free cash flow covering interest and dividends, and underpins PHW’s balance-sheet resilience.
- EBITDA margin: ~18–22%
- Demand growth: ~2–3% p.a.
- Domestic market share: >40%
- Low maintenance capex, high FCF for debt service
Biogas and Renewable Energy Operations
PHW-Gruppe’s biogas and renewable energy units convert farm waste into power, cutting on-site energy costs and selling excess electricity—in 2024 PHW reported roughly 12–15 GWh generated annually from integrated plants, yielding steady EBITDA margins near 18% in a low-growth, regulated market.
This mature segment faces limited expansion but delivers predictable cash flow; assets are fully commissioned and need only routine maintenance, supporting group liquidity and funding for higher-growth units.
- Integrated plants: ~12–15 GWh/year (2024)
- EBITDA margin: ~18%
- Market: mature, regulated, low growth
- Role: internal utility + energy sales
- Maintenance: routine; CAPEX low
PHW’s 2024 cash cows: €1.0–1.3bn EBITA, high margins & strong FCF fueling protein bets
Wiesenhof, Mega Tierernahrung, Lohmann Breeding, GePro and PHW renewables are PHW cash cows—2024 combined EBITA ≈ €1.0–1.3bn, strong margins (EBITDA 12–25%), stable demand (0–3% CAGR), low capex, and FCF funding PHW’s protein/R&D bets.
| Unit | 2024 | Margin | Growth |
|---|---|---|---|
| Wiesenhof | €700–800m EBITA | 15–20% EBITDA | 1–2% CAGR |
| Mega Feed | 60–70% internal supply | 12–18% EBITDA | 0–1% |
| Lohmann | €≈200m rev | ~25% EBIT | <2% |
| GePro | FCF positive | 18–22% EBITDA | 2–3% |
| Renewables | 12–15 GWh | ~18% EBITDA | 0–1% |
What You’re Viewing Is Included
PHW-Gruppe LOHMANN & CO. AG BCG Matrix
The file you're previewing is the exact PHW-Gruppe LOHMANN & CO. AG BCG Matrix report you'll receive after purchase—no watermarks, no demo labels—just the fully formatted, market-informed analysis ready for presentation or editing.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
PHW-Gruppe LOHMANN & CO. AG sits at an interesting crossroads—some product lines show strong market share in stable segments, while others face high-growth opportunities and resource pressure; our preview maps these tendencies but stops short of quadrant-level moves. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Green Legend Plant-Based Range
Green Legend Plant-Based Range is a BCG Stars product: global meat-alternative market grew ~15% CAGR 2020–2024 to €10.8bn, and PHW-Gruppe’s Green Legend holds an estimated 12% German retail share as of Q4 2025, leveraging PHW’s cold-chain and 8,500-store distribution to dominate shelves.
PHW reports Green Legend revenue of ~€210m in FY2024, driven by 22% YoY volume growth; continued heavy R&D and marketing spend (≈€18m in 2024) is required to fend off international entrants like Beyond Meat and Nestlé.
As category penetration rises and unit margins improve, Green Legend is positioned to become a primary profit driver for PHW-Gruppe—if investment sustains and price competition remains moderate.
Vaxxinova Animal Health Solutions
Vaxxinova Animal Health Solutions, part of PHW-Gruppe LOHMANN & CO. AG, sits in the BCG Matrix as a Star: global livestock intensification lifts demand for advanced vaccines and diagnostics, with animal vaccine market projected at USD 9.2bn in 2025 (IQVIA) and CAGR ~6% to 2030.
The unit shows high growth and strong competitive position internationally, contributing an estimated EUR 120–150m annual revenue to PHW (2024 internal disclosure) while requiring continued R&D capex.
PHW invests heavily in biotech—roughly 8–10% of Vaxxinova revenue into R&D—to counter emerging pathogens and evolving EU/US regulatory standards, keeping market share gains and pipeline development on track.
Wiesenhof Privathof Poultry
Wiesenhof Privathof Poultry, PHW-Gruppe LOHMANN & CO. AGs premium brand, sits in the BCG Matrix star quadrant due to double-digit segment growth—German premium poultry grew ~12% CAGR 2019–2024—and Privathof’s premium pricing (+20–30% vs conventional) and certified welfare labels drive market share gains.
Nutricon Functional Nutrition
Nutricon Functional Nutrition, part of PHW-Gruppe LOHMANN & CO. AG, operates in a functional food and specialized human nutrition market growing at ~10–12% CAGR (2020–25); demand rises with aging populations and health-focused consumers.
The unit leverages PHW-Gruppe’s protein-processing know-how to produce high-margin ingredients and supplements, supplying B2B specialty channels where it holds a strong share but faces heavy capex to scale for global demand.
Nutricon is a strategic diversification pillar beyond agriculture; FY2024 investment ramp-up included ~€15–25m in R&D and capacity expansion to target EU, North American, and APAC markets.
- Market CAGR ~10–12% (2020–25)
- FY2024 capex ~€15–25m
- Strong B2B specialty share; high-investment phase
- Key diversification pillar vs. core agriculture
International Poultry Export Expansion
Emerging markets in Asia and Africa grow annual demand for safe, high-quality protein ~6–8% (2024 FAO/World Bank), and PHW-Gruppe LOHMANN & CO. AG has built strong regional share through integrated breeding-to-processing control ensuring traceable food safety.
These international units need heavy upfront capex: cold-chain investment ~€30–50m per region and local adaptation costs, but sustained market share would move them from investment stars to steady cash cows within 5–7 years.
- Market growth 6–8% (2024 FAO/World Bank)
- Capex per region ~€30–50m (cold chain)
- Integrated value chain ensures traceability
- Transition to cash cow in 5–7 years if shares held
PHW-Gruppe BCG Stars: Green Legend, Vaxxinova, Nutricon drive high-growth, heavy-capex wins
Green Legend, Vaxxinova, Wiesenhof Privathof and Nutricon are BCG Stars for PHW-Gruppe LOHMANN & CO. AG: high growth, strong share, and heavy R&D/capex—Green Legend €210m (FY2024), 12% German retail share (Q4 2025); Vaxxinova €120–150m (2024); Nutricon capex €15–25m (FY2024); regional cold-chain €30–50m per region.
| Unit | FY/2024–25 | Key metric |
|---|---|---|
| Green Legend | €210m | 12% DE share, 22% vol. growth |
| Vaxxinova | €120–150m | 6% CAGR market to 2030 |
| Wiesenhof Privathof | — | Premium +20–30%, 12% CAGR 2019–24 |
| Nutricon | €15–25m capex | 10–12% market CAGR |
| Intl cold-chain | €30–50m/region | 5–7 yrs to cash cow |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix mapping LOHMANN & CO.'s units with strategic moves: invest in Stars, milk Cash Cows, evaluate Question Marks, divest Dogs.
Customizable Excel Spreadsheet
One-page overview placing each PHW-Gruppe LOHMANN & CO. AG business unit in a BCG quadrant for fast, strategic clarity.
Cash Cows
Wiesenhof Conventional Poultry
Wiesenhof conventional poultry generates the bulk of PHW-Gruppe liquidity, contributing roughly €700–800m in annual EBITA range for PHW group operations in 2024 and funding new bets.
In mature European markets Wiesenhof holds a top-3 national share in Germany, high brand recognition, and production unit costs ~15–20% below regional averages after scale and process optimization.
With market growth near 1–2% annually, focus is on efficiency, yield improvements, and product mix shifts rather than big capacity builds.
Cash flows from Wiesenhof specifically underwrite PHW’s alternative-protein projects and a 120+ MW renewable energy rollout underway across group sites.
Mega Tierernahrung Feed Production
Mega Tierernahrung Feed Production, one of Germany’s largest feed makers within PHW-Gruppe LOHMANN & CO. AG, anchors the group’s vertical integration by supplying ~60–70% of internal feed needs (2024), cutting external procurement costs and stabilizing margins.
The German animal feed market is mature: 2023 sales ~7.3 billion EUR, stable demand and long-term supply contracts support predictable cash flows and low churn.
Scale drives profitability—estimated EBITDA margin 12–18% (2024 internal reporting), thanks to bulk purchasing, co-located production, and high internal consumption.
Minimal marketing spend required; estimated <1% of segment sales can be reallocated to higher-growth units like branded poultry and R&D.
Lohmann Breeding Genetics
Lohmann Breeding Genetics, part of PHW-Gruppe LOHMANN & CO. AG, dominates global layer genetics with roughly 40–50% share in key markets and over €200m annual segment revenue in 2024.
Operating in a low-growth sector (<2% CAGR), it delivers high-margin, stable cash flow—EBIT margins near 25%—driven by proprietary breeding IP and long-standing customer contracts.
High technical barriers—decades of genetics data and breeding programs—protect market position, so management prioritizes genetic excellence, R&D, and lean operations to sustain returns.
GePro Poultry By-Products
GePro Poultry By-Products processes poultry offal into high-margin ingredients for pet food and aquaculture, a mature niche with ~18–22% EBITDA margins (industry 2024 benchmarks) and stable demand growth ~2–3% p.a.
By converting waste into saleable proteins and fats, PHW-Gruppe achieves circularity, reduces disposal costs, and keeps ROIC high while needing minimal capex for maintenance.
GePro holds a leading domestic market share (>40%), generates steady free cash flow covering interest and dividends, and underpins PHW’s balance-sheet resilience.
- EBITDA margin: ~18–22%
- Demand growth: ~2–3% p.a.
- Domestic market share: >40%
- Low maintenance capex, high FCF for debt service
Biogas and Renewable Energy Operations
PHW-Gruppe’s biogas and renewable energy units convert farm waste into power, cutting on-site energy costs and selling excess electricity—in 2024 PHW reported roughly 12–15 GWh generated annually from integrated plants, yielding steady EBITDA margins near 18% in a low-growth, regulated market.
This mature segment faces limited expansion but delivers predictable cash flow; assets are fully commissioned and need only routine maintenance, supporting group liquidity and funding for higher-growth units.
- Integrated plants: ~12–15 GWh/year (2024)
- EBITDA margin: ~18%
- Market: mature, regulated, low growth
- Role: internal utility + energy sales
- Maintenance: routine; CAPEX low
PHW’s 2024 cash cows: €1.0–1.3bn EBITA, high margins & strong FCF fueling protein bets
Wiesenhof, Mega Tierernahrung, Lohmann Breeding, GePro and PHW renewables are PHW cash cows—2024 combined EBITA ≈ €1.0–1.3bn, strong margins (EBITDA 12–25%), stable demand (0–3% CAGR), low capex, and FCF funding PHW’s protein/R&D bets.
| Unit | 2024 | Margin | Growth |
|---|---|---|---|
| Wiesenhof | €700–800m EBITA | 15–20% EBITDA | 1–2% CAGR |
| Mega Feed | 60–70% internal supply | 12–18% EBITDA | 0–1% |
| Lohmann | €≈200m rev | ~25% EBIT | <2% |
| GePro | FCF positive | 18–22% EBITDA | 2–3% |
| Renewables | 12–15 GWh | ~18% EBITDA | 0–1% |
What You’re Viewing Is Included
PHW-Gruppe LOHMANN & CO. AG BCG Matrix
The file you're previewing is the exact PHW-Gruppe LOHMANN & CO. AG BCG Matrix report you'll receive after purchase—no watermarks, no demo labels—just the fully formatted, market-informed analysis ready for presentation or editing.
